Supplementary Materials for

In Vivo CRISPR Gene Editing in Patients with Herpes Stromal Keratitis

Anji Wei1[†], Di Yin2[†], Zimeng Zhai1[†], Sikai Ling3, Huangying Le2, Lijia Tian1, Jianjiang Xu1, Soren R Paludan4, Yujia Cai2^{*}, Jiaxu Hong1, 5, 6^{*}.

[†]These authors contributed equally to this work. *Corresponding author. Email: JH: Jiaxu.hong@fdeent.org, YC: yujia.cai@sjtu.edu.cn.

Other Supplementary Materials for this manuscript include the following:

Supplemental Movie

		1 day	7 days	1 month	2 months	3 months	6 months	12 months
		pre-injection	post-injection	post-injection	post-injection	post-injection	post-injection	post-injection
	Best-corrected visual acuity	Light perception	Finger count	Finger count	Finger count	Finger count	20/100	20/100
Patient 1	Intraocular pressure (mmHg)	Undetectable	12.0	10.4	16	15.3	8	21.3
	HSV-1 tests (Ct value)	21.35 (Cornea) 28.37 (Aqueous) 30.55*(Tear swab)	- 24.09(Tear swab) -	28.37(Tear swab) 31.49(Tear swab) 31.08(Tear swab)	-	-	-	-
	Best-corrected visual acuity	Hand motion	20/250	20/167	20/100	20/67	20/133	20/133
Patient 2	Intraocular pressure (mmHg)	Undetectable	11.0	16.3	16.4	12.4	7.3	15.0
	HSV-1 tests (Ct value)	26.34 (Cornea) 36.50 (Aqueous) 35.01*(Tear swab)	-	-	- -	- -	- -	-
	Best-corrected visual acuity	Hand motion	Hand motion	Hand motion	Hand motion	Hand motion	Hand motion	Finger count
Patient 3	Intraocular pressure (mmHg)	Undetectable	n.a.	15.0	24.1	18.5	18.1	19.3
Patient 3	HSV-1 tests (Ct value)	34.9 (Cornea) - (Aqueous) 29.5 (Tear swab)	-	-	-	-	-	-

Table S1. Visual acuity, intraocular pressure and virus tests.

*Mean HSV-1 titer (Ct value) of three simultaneously sampled tear swabs; n.a., not available; -, Ct value undetectable.

Patient	Adverse Event	Start Date	End Date	Placebo Related	Severity	Outcome	Treatment
1	corneal edema	11/2020	11/2020	possibly related	mild	resolved	concomitant medication
	conjunctival injection	11/2020	11/2020	unlikely to be related	mild	resolved	concomitant medication
	hyphema	11/2020	11/2020	unrelated	mild	resolved	none
	neurotrophic keratitis	5/2021	/	unrelated	mild	unresolved	concomitant medication
	uncontrolled corneal ulcer	9/2021	11/2021	unrelated	moderate	resolved	penetrating keratoplasty
	cataract	n.a.	11/2021	unrelated	mild	resolved	cataract surgery
	secondary glaucoma	10/2021	12/2021	unrelated	mild	resolved	concomitant medication
2	corneal edema	1/2021	1/2021	possibly related	mild	resolved	concomitant medication
	conjunctival injection	1/2021	1/2021	unlikely to be related	mild	resolved	concomitant medication
	itching	2/2021	3/2021	unrelated	mild	resolved	concomitant medication
	endophthalmitis	7/2021	7/2021	unrelated	moderate	resolved	vitrectomy and antibiotic injection
	cataract	n.a.	/	unrelated	mild	unresolved	none
3	corneal edema	5/2021	5/2021	possibly related	mild	resolved	concomitant medication
	conjunctival injection	5/2021	5/2021	unlikely to be related	mild	resolved	concomitant medication
	graft rejection	8/2021	10/2021	unrelated	mild	resolved	concomitant medication
	secondary glaucoma	7/2021	8/2021	unrelated	mild	resolved	concomitant medication
	cataract	n.a.	/	unrelated	mild	unresolved	none

Table S2. Visual acuity, intraocular pressure and virus tests.

20 HSV-1 KOS UL23 MASYPCHQHA SAFDQAARSR GHSNRRTALR PRRQQEATEV RLEQKMPTLL RVYIDGPHGM 60 HSV-1 17+ UL23 MASYPCHQHA SAFDQAARSR GHNNRRTALR PRRQQKATEV RLEQKMPTLL RVYIDGPHGM 60 Patient 1 UL23 - - - YPCHQHA SAFDQAARSR GHSNRRTALR PRRQQEATEV RLEQKMPTLL RVYIDGPHGM 57 Patient 2 UL23 --- YPCHQHA SAFDQAARSR GHSNRRTALR PRRQQEATEV RLEQKMPTLL RVYIDGPHGM 57 Patient 3 UL23 --- YPCHQHA SAFDQAARSR GHSNRRTALR PRRQQEATEV RLEQKMPTLL RVYIDGPHGM 57 120 80 100 HSV-1 KOS UL23 GKTTTTQLLV ALGSRDDIVY VPEPMTYWQV LGASETIANI YTTQHRLDQG EISAGDAAVV 120 HSV-117+ UL23 GKTTTTQLLV ALGSRDDIVY VPEPMTYWRV LGASETIANI YTTQHRLDQG EISAGDAAVV 120 Patient 1 UL23 GKTTTTQLLV ALGSRDDIVY VPEPMTYWQV LGASETIANI YTTQHRLDQG EISAGDAAVV 117 Patient 2 UL23 GKTTTTQLLV ALGSRDDIVY VPEPMTYWQV LGASETIANI YTTQHRLDQG EISAGDAAVV 117 Patient 3 UL23 GKTTTTQLLV ALGSRDDIVY VPEPMTYWQV LGASETIANI YTTQHRLDQG EISAGDAAVV 117 140 HSV-1 KOS UL23 MTSAQITMGM PYAVTDAVLA PHIGGEAGSS HAPPPALTLI FDRHPIAALL CYPAARYLMG 180 HSV-1 17+ UL23 MTSAQITMGM PYAVTDAVLA PHIGGEAGSS HAPPPALTLI FDRHPIAALL CYPAARYLMG 180 Patient 1 UL23 MTSAQITMGM PYAVTDAVLA PHIGGEAGSS HAPPPALTLI FDRHPIAALL CYPAARYLMG 177 Patient 2 UL23 MTSAQITMGM PYAVTDAVLA PHIGGEAGSS HAPPPALTLI FDRHPIAALL CYPAARYLMG 177 Patient 3 UL23 MTSAQITMGM PYAVTDAVLA PHIGGEAGSS HAPPPALTLI FDRHPIAALL CYPAARYLMG 177 200 220 240 HSV-1 KOS UL23 SMTPQAVLAF VALIPPTLPG TNIVLGALPE DRHIDRLAKR QRPGERLDLA MLAAIRRVYG 240 HSV-117+UL23 SMTPQAVLAF VALIPPTLPG TNIVLGALPE DRHIDRLAKR QRPGERLDLA MLAAIRRVYG 240 Patient 1 UL23 SMTPQAVLAF VALIPPTLPG TNIVLGALPE DRHIDRLAKR QRPGERLDLA MLAAIRRVYG 237 Patient 2 UL23 SMTPQAVLAF VALIPPTLPG TNIVLGALPE DRHIDRLAKR QRPGERLDLA MLAAIRRVYG 237 Patient 3 UL23 SMTPQAVLAF VALIPPTLPG TNIVLGALPE DRHIDRLAKR QRPGERLDLA MLAAIRRVYG 237 260 280 300 HSV-1 KOS UL23 LLANTVRYLQ GGGSWREDWG QLSGTAVPPQ GAEPQSNAGP RPHIGDTLFT LFRAPELLAP 300 HSV-117+UL23 LLANTVRYLQ GGGSWREDWG QLSGAAVPPQ GAEPQSNAGP RPHIGDTLFT LFRAPELLAP 300 Patient 1 UL23 LLANTVRYLQ GGGSWREDWG QLSGTAVPPQ GAEPQSNAGP RPHIGDTLFT LFRAPELLAP 297 Patient 2 UL23 LLANTVRYLQ GGGSWREDWG QLSGTAVPPQ GAEPQSNAGP RPHIGDTLFT LFRAPELLAP 297 Patient 3 UL23 LLANTVRYLQ GGGSWREDWG QLSGTAVPPQ GAEPQSNAGP RPHIGDTLFT LFRAPELLAP 297 320 340 360 HSV-1 KOS UL23 NGDLYNVFAW ALDVLAKRLR PMHVFILDYD QSPAGCRDAL LQLTSGMVQT HVTTPGSIPT 360 HSV-117+UL23 NGDLYNVFAW ALDVLAKRLR PMHVFILDYD QSPAGCRDAL LQLTSGMVQT HVTTPGSIPT 360 Patient 1 UL23 NGDLYNVFAW ALDVLAKRLR PMHVFILDYD QSPAGCRDAL LQLTSGMVQT HVTTPGSIPT 357 Patient 2 UL23 NGDLYNVFAW ALDVLAKRLR PMHVFILDYD QSPAGCRDAL LQLTSGMVQT HVTTPGSIPT 357 Patient 3 UL23 NGDLYNVFAW ALDVLAKRLR PMHVFILDYD QSPAGCRDAL LQLTSGMVQT HVTTPGSIPT 357 HSV-1 KOS UL23 ICDLARTFAR EMGEAN 377 HSV-1 17+ UI 23 ICDLARTEAR EMGEAN 377

Patient 1 UL23 I CDLARTFAR EMGEAN 374 Patient 2 UL23 I CDLARTFAR EMGEAN 374 Patient 3 UL23 I CDLARTFAR EMGEAN 374

A

HSV-1 KOS UL30 MFSGGGGPLS PGGKSAARAA SGFFAPAGPR GAGRGPPPCL RQNFYNPYLA PVGTQQKPTG 60 HSV-1 17+ UL30 MFSGGGGPLS PGGKSAARAA SGFFAPAGPR GASRGPPPCL RQNFYNPYLA PVGTQQKPTG 60 Patient 1 UL30 ------RAA SGFFAPAGPR GASRGPPPCL RQNFYNPYLA PVGTQQKPTG 43 Patient 2 UL30 ------RAA SGFFAPAGPR GAGRGPPPCL RQNFYNPYLA PVGTQQKPTG 43 Patient 3 UL30 ------ RAA SGFFAPAGPR GAGRGPPPCL RQNFYNPYLA PVGTQQKPTG 43 80 100 120 HSV-1 KOS UL30 PTORHTYYSE CDEFRFIAPR VLDEDAPPEK RAGVHDGHLK RAPKVYCGGD ERDVLRVGSG 120 HSV-1 17+ UL30 PTQRHTYYSE CDEFRFIAPR VLDEDAPPEK RAGVHDGHLK RAPKVYCGGD ERDVLRVGSG 120 Patient 1 UL30 PTQRHTYYSE CDEFRFIAPR VLDEDAPPEK RAGVHDGHLK RAPKVYCGGD ERDVLRVGSG 103 Patient 2 UL30 PTQRHTYYSE CDEFRFIAPR VLDEDAPPEK RAGVHDGHLK RAPKVYCGGD ERDVLRVGSG 103 Patient 3 UL30 PTQRHTYYSE CDEFRFIAPR VLDEDAPPEK RAGVHDGHLK RAPKVYCGGD ERDVLRVGSG 103 140 HSV-1 KOS UL30 GFWPRRSRLW GGVDHAPAGF NPTVTVFHVY DILENVEHAY GMRAAQFHAR FMDAITPTGT 180 HSV-1 17+ UL30 GFWPRRSRLW GGVDHAPAGF NPTVTVFHVY DILENVEHAY GMRAAQFHAR FMDAITPTGT 180 Patient 1 UL30 GFWPRRSRLW GGVDHAPAGF NPTVTVFHVY DILENVEHAY GMRAAQFHAR FMDAITPTGT 163 Patient 2 UL30 GFWPRRSRLW GGVDHAPAGF NPTVTVFHVY DILENVEHAY GMRAAQFHAR FMDAITPTGT 163 Patient 3 UL30 GFWPRRSRLW GGVDHAPAGF NPTVTVFHVY DILENVEHAY GMRAAQFHAR FMDAITPTGT 163 200 220 240 HSV-1 KOS UL30 VITLLGLTPE GHRVAVHVYG TRQYFYMNKE EVDRHLQCRA PRDLCERMAA ALRESPGASF 240 HSV-1 17+ UL30 VITLLGLTPE GHRVAVHVYG TRQYFYMNKE EVDRHLQCRA PRDLCERMAA ALRESPGASF 240 Patient 1 UL30 VITLLGLTPE GHRVAVHVYG TRQYFYMNKE EVDRHLQCRA PRDLCERMAA ALRESPGASF 223 Patient 2 UL30 VITLLGLTPE GHRVAVHVYG TRQYFYMNKE EVDRHLQCRA PRDLCERMAA ALRESPGASF 223 Patient 3 UL30 VITLLGLTPE GHRVAVHVYG TRQYFYMNKE EVDRHLQCRA PRDLCERMAA ALRESPGASF 223 260 280 300 HSV-1 KOS UL30 RGISADHFEA EVVERTDVYY YETRPALFYR VYVRSGRVLS YLCDNFCPAI KKYEGGVDAT 300 HSV-1 17+ UL30 RGISADHFEA EVVERTDVYY YETRPALFYR VYVRSGRVLS YLCDNFCPAI KKYEGGVDAT 300 Patient 1 UL30 RGISADHFEA EVVERTDVYY YETRPALFYR VYVRSGRVLS YLCDNFCPAI KKYEGGVDAT 283 Patient 2 UL30 RGI SADHFEA EVVERTDVYY YETRPALFYR VYVRSGRVLS YLCDNFCPAI KKYEGGVDAT 283 Patient 3 UL30 RGISADHFEA EVVERTDVYY YETRPALFYR VYVRSGRVLS YLCDNFCPAI KKYEGGVDAT 283 320 340 360 HSV-1 KOS UL30 TRFILDNPGF VTFGWYRLKP GRNNTLAQPR APMAFGTSSD VEFNCTADNL AIEGGMSDLP 360 GRNNTLAQPR APMAFGTSSD VEFNCTADNL AIEGGMSDLP 360 HSV-1 17+ UL30 TRFILDNPGF VTFGWYRLKP Patient 1 UL30 TRFILDNPGF VTFGWYRLKP GRNNTLAQPR APMAFGTSSD VEFNCTADNL AIEGGMSDLP 343 Patient 2 UL30 TRFILDNPGF VTFGWYRLKP GRNNTLAQPR APMAFGTSSD VEFNCTADNL AIEGGMSDLP 343 Patient 3 UL30 TRFILDNPGF VTFGWYRLKP GRNNTLAQPR APMAFGTSSD VEFNCTADNL AIEGGMSDLP 343 380 400 420 HSV-1 KOS UL30 AYKLMCFDIE CKAGGEDELA FPVAGHPEDL VIQISCLLYD LSTTALEHVL LFSLGSCDLP 420 HSV-1 17+ UL30 AYKLMCFDIE CKAGGEDELA FPVAGHPEDL VIQISCLLYD LSTTALEHVL LFSLGSCDLP 420 Patient 1 UL30 AYKLMCFDIE CKAGGEDELA FPVAGHPEDL VIQISCLLYD LSTTALEHVL LFSLGSCDLP 403 Patient 2 UL30 AYKLMCFDIE CKAGGEDELA FPVAGHPEDL VIQISCLLYD LSTTALEHVL LFSLGSCDLP 403 Patient 3 UL30 AYKLMCFDIE CKAGGEDELA FPVAGHPEDL VIQISCLLYD LSTTALEHVL LFSLGSCDLP 403 440 460 480 HSV-1 KOS UL30 ESHLNELAAR GLPTPVVLEF DSEFEMLLAF MTLVKQYGPE FVTGYNIINF DWPFLLAKLT 480 HSV-1 17+ UL30 ESHLNELAAR GLPTPVVLEF DSEFEMLLAF MTLVKQYGPE FVTGYNIINF DWPFLLAKLT 480 Patient 1 UL30 ESHLNELAAR GLPTPVVLEF DSEFEMLLAF MTLVKQYGPE FVTGYNIINF DWPFLLAKLT 463 Patient 2 UL30 ESHLNELAAR GLPTPVVLEF DSEFEMLLAF MTLVKQYGPE FVTGYNIINF DWPFLLAKLT 463 Patient 3 UL30 ESHLNELAAR GLPTPVVLEF DSEFEMLLAF MTLVKQYGPE FVTGYNIINF DWPFLLAKLT 463 500 520 540 HSV-1 KOS UL30 DIYKVPLDGY GRMNGRGVFR VWDIGQSHFQ KRSKIKVNGM VNIDMYGIIT DKIKLSSYKL 540 HSV-1 17+ UL30 DIYKVPLDGY GRMNGRGVFR VWDIGQSHFQ KRSKIKVNGM VNIDMYGIIT DKIKLSSYKL 540 Patient 1 UL30 DIYKVPLDGY GRMNGRGVFR VWDIGQSHFQ KRSKIKVNGM VNIDMYGIIT DKIKLSSYKL 523 Patient 2 UL30 DIYKVPLDGY GRMNGRGVFR VWDIGQSHFQ KRSKIKVNGM VNIDMYGIIT DKIKLSSYKL 523 Patient 3 UL30 DIYKVPLDGY GRMNGRGVFR VWDIGQSHFQ KRSKIKVNGM VNIDMYGIIT DKIKLSSYKL 523 560 580 600 HSV-1 KOS UL30 NAVAEAVLKD KKKDLSYRDI PAYYATGPAQ RGVIGEYCIQ DSLLVGQLFF KFLPHLELSA 600 HSV-1 17+ UL30 NAVAEAVLKD KKKDLSYRDI PAYYAAGPAQ RGVIGEYCIQ DSLLVGQLFF KFLPHLELSA 600 Patient 1 UL30 NAVAEAVLKD KKKDLSYRDI PAYYAAGPAQ RGVIGEYCIQ DSLLVGQLFF KFLPHLELSA 583 Patient 2 UL30 NAVAEAVLKD KKKDLSYRDI PAYYATGPAQ RGVIGEYCIQ DSLLVGQLFF KFLPHLELSA 583 Patient 3 UL30 NAVAEAVLKD KKKDLSYRDI PAYYATGPAQ RGVIGEYCIQ DSLLVGQLFF KFLPHLELSA 583 620 640 660 HSV-1 KOS UL30 VARLAGINIT RTIYDGQQIR VFTCLLRLAD QKGFILPDTQ GRFRGAGGEA PKRPAAARED 660 HSV-1 17+ UL30 VARLAGINIT RTIYDGQQIR VFTCLLRLAD QKGFILPDTQ GRFRGAGGEA PKRPAAARED 660 Patient 1 UL30 VARLAGINIT RTIYDGQQIR VFTCLLRLAD QKGFILPDTQ GRFRGAGGEA PKRPAAARED 643 Patient 2 UL30 VARLAGINIT RTIYDGQQIR VFTCLLRLAD QKGFILPDTQ GRFRGAGGEA PKRPAAARED 643 Patient 3 UL30 VARLAGINIT RTIYDGQQIR VFTCLLRLAD QKGFILPDTQ GRFRGAGGEA PKRPAAARED 643 680 700 720 HSV-1 KOS UL30 EERPEEEGED EDEREEGGGE REPEGARETA GRHVGYQGAR VLDPTSGFHV NPVVVFDFAS 720 HSV-1 17+ UL30 EERPEEEGED EDEREEGGEE REPEGARETA GRHVGYQGAR VLDPTSGFHV NPVVVFDFAS 720 Patient 1 UL30 EERPEEEGED EDEREEGGGE REPEGARETA GRHVGYQGAR VLDPTSGFHV NPVVVFDFAS 703 Patient 2 UL30 EERPEEEGED EDEREEGGGE REPEGARETA GRHVGYQGAR VLDPTSGFHV NPVVVFDFAS 703 Patient 3 UL30 EERPEEEGED EDEREEGGGE REPEGARETA GRHVGYQGAR VLDPTSGFHV NPVVVFDFAS 703

740 780 HSV-1 KOS UL30 LYPSIIQAHN LCFSTLSLRA DAVAHLEAGK DYLEIEVGGR RLFFVKAHVR ESLLSILLRD 780 HSV-1 17+ UL30 LYPSI IQAHN LCFSTLSLRA DAVAHLEAGK DYLEIEVGGR RLFFVKAHVR ESLLSILLRD 780 Patient 1 UL30 LYPSI IQAHN LCFSTLSLRA DAVAHLEAGK DYLEIEVGGR RLFFVKAHVR ESLLSILLRD 763 Patient 2 UL30 LYPSI IQAHN LCFSTLSLRA DAVAHLEAGK DYLEIEVGGR RLFFVKAHVR ESLLSILLRD 763 Patient 3 UL30 LYPSI IQAHN LCFSTLSLRA DAVAHLEAGK DYLEIEVGGR RLFFVKAHVR ESLLSI LLRD 763 800 820 HSV-1 KOS UL30 WLAMRKQIRS RIPQSSPEEA VLLDKQQAAJ KVVCNSVYGF TGVQHGLLPC LHVAATVTT | 840 KVVCNSVYGF TGVQHGLLPC HSV-1 17+ UL30 WLAMRKQIRS RIPQSSPEEA VLLDKQQAAI LHVAATVTTI 840 KVVCNSVYGF LHVAATVTTI 823 Patient 1 UL30 WLAMRKQIRS RIPQSSPEEA VLLDKQQAAI TGVQHGLLPC KVVCNSVYGF Patient 2 UL30 WLAMRKQIRS RIPQSSPEEA VLLDKQQAAI TGVQHGLLPC LHVAATVTTI 823 Patient 3 UL30 WLAMRKQ IRS RIPQSSPEEA VLLDKQQAAI KVVCNSVYGF **TGVQHGLLPC LHVAATVTT** 823 860 880 900 HSV-1 KOS UL30 GREMLLATRE YVHARWAAFE QLLADFPEAA DMRAPGPYSM **RIIYGDTDSI FVLCRGLTAA** 900 QLLADFPEAA DMRAPGPYSM HSV-1 17+ UL30 GREMLLATRE YVHARWAAFE RIIYGDTDSI FVLCRGLTAA 900 QLLADFPEAA DMRAPGPYSM Patient 1 UL30 **GREMLLATRE** YVHARWAAFE RIIYGDTDSI FVLCRGLTAA 883 QLLADFPEAA DMRAPGPYSM Patient 2 UL30 GREMLLATRE **YVHARWAAFE** RIIYGDTDSI FVLCRGLTAA 883 YVHARWAAFE QLLADFPEAA DMRAPGPYSM RILYGDTDSI Patient 3 UL30 **GREMLLATRE** FVLCRGLTAA 883 920 HSV-1 KOS UL30 GLTAMGDKMA SHISRALFLP PIKLECEKTF TKLLLIAKKK YIGVIYGGKM LIKGVDLVRK 960 HSV-1 17+ UL30 GLTAVGDKMA SHISRALFLP PIKLECEKTF TKLLLIAKKK YIGVIYGGKM LIKGVDLVRK 960 Patient 1 UL30 GLTAVGDKMA SHISRALFLP PIKLECEKTF TKLLLIAKKK YIGVIYGGKM LIKGVDLVRK 943 SHISRALFLP PIKLECEKTF YIGVIYGGKM LIKGVDLVRK 943 Patient 2 UL30 GLTAMGDKMA TKLLLIAKKK Patient 3 UL30 GL TAMGD KMA SHISRALFLP PIKLECEKTF TKLLLIAKKK YIGVIYGGKM LIKGVDLVRK 943 1,000 1.020 980 HSV-1 KOS UL30 NNCAFINRTS RALVDLLFYD DTVSGAAAAL AERPAEEWLA RPLPEGLQAF GAVLVDAHRR 1020 HSV-1 17+ UL30 NNCAF INRTS RALVDLLFYD DTVSGAAAAL AERPAEEWLA RPLPEGLQAF **GAVLVDAHRR** 1020 Patient 1 UL30 NNCAFINRTS RALVDLLFYD DTVSGAAAAL AERPAEEWLA **RPLPEGLQAF GAVLVDAHRR** 1003 Patient 2 UL30 NNCAFINRTS RALVDLLFYD DTVSGAAAAL AERPAEEWLA **RPLPEGLQAF GAVLVDAHRR** 1003 Patient 3 UL30 NNCAFINRTS RALVDLLFYD DTVSGAAAAL AERPAEEWLA RPLPEGLQAF GAVLVDAHRR 1003 1,040 1.060 1.080 HSV-1 KOS UL30 ITDPERDIQD FVLTAELSRH PRAYTNKRLA HLTVYYKLMA RRAQVPSIKD RIPYVIVAQT 1080 HSV-1 17+ UL30 ITDPERDIQD FVLTAELSRH PRAYTNKRLA HLTVYYKLMA RRAQVPSIKD RIPYVIVAQT 1080 Patient 1 UL30 | TDPERD | QD FVLTAELSRH PRAYTNKRLA HLTVYYKLMA RRAQVPSIKD RIPYVIVAQT 1063 Patient 2 UL30 ITDPERDIQD FVLTAELSRH PRAYTNKRLA HLTVYYKLMA RRAQVPSIKD RIPYVIVAQT 1063 Patient 3 UL30 ITDPERDIQD FVLTAELSRH PRAYTNKRLA HLTVYYKLMA RRAQVPSIKD RIPYVIVAQT 1063 1,100 1,120 1.140 HSV-1 KOS UL30 REVEETVARL AALRELDAAA PGDEPAPPAA LPSPAKRPRE TPSHADPPGG ASKPRKLLVS 1140 HSV-1 17+ UL30 REVEETVARL AALRELDAAA PGDEPAPPAA LPSPAKRPRE TPSPADPPGG ASKPRKLLVS 1140 Patient 1 UL30 REVEETVARL AALRELDAAA PGDEPAPPAA LPSPAKRPRE TPSPADPPGG ASKPRKLLVS 1123 Patient 2 UL30 REVEETVARL AALRELDAAA PGDEPAPPAA LPSPAKRPRE **TPSHADPPGG ASKPRKLLVS** 1123 Patient 3 UL30 REVEETVARL AALRELDAAA PGDEPAPPAA LPSPAKRPRE TPSHADPPGG ASKPRKLLVS 1123 1,160 1.200 1,180 HSV-1 KOS UL30 ELAEDPAYAI AHGVALNTDY YFSHLLGAAC VTFKALFGNN AKITESLLKR FIPEVWHPPD 1200 HSV-1 17+ UL30 ELAEDPAYA AHGVALNTDY YFSHLLGAAC VTFKALFGNN AKITESLLKR FIPEVWHPPD 1200 Patient 1 UL30 ELAEDPAYA AHGVALNTDY YFSHL 1152 Patient 2 UL30 ELAEDPAYAI AHGVALNTDY YFSHL 1152 Patient 3 UL30 ELAEDPAYAI AHGVALNTDY YFSHL 1152 1,220 HSV-1 KOS UL30 DVAARLRAAG FGAVGAGATA EETRRMLHRA FDTLA 1235 HSV-1 17+ UL30 DVAARLRTAG FGAVGAGATA EETRRMLHRA FDTLA 1235 Patient 1 UL30 -----**--- 1**152 Patient 2 UI 30 1152 Patient 3 UL30 1152

Fig. S1. Amino acids alignment for TK and DNA pol. HSV-1 strains were isolated from the three participants and sequenced for genes encoding thymidine kinase (TK, UL23) and DNA polymerase (DNA pol, UL30). Letter in red color indicated changed amino acids in TK (**A**) and DNA pol (**B**). HSV-1 KOS and 17syn+ strains were used as references. Only amino-acid changes different from both KOS and 17syn+ simultaneously are considered as ACV resistant mutations.



Fig. S2. Postoperative B-scan ultrasonography of patient 3. B-scan ultrasonography of the patient 3 on 7 days (A), 1 month (B), 3 months (C) and 6 months (D) post-injection. Continuous ribbon-like echo was found in the posterior vitreous body, indicating vitreous opacity with posterior detachment.



Fig. S3. Postoperative B-scan ultrasonography of patient 2. B-scan ultrasonography results of patient 2 on 6 months (**A**) and 9 months (**B**) post-injection showed no remarkable changes in the vitreous body.



Fig. S4. Postoperative B-scan ultrasonography of patient 1. B-scan ultrasonography of patient 1 on 7 days (A), 1 month (B), 6 months (C) and 12 months (D) post-injection revealed no remarkable changes in the vitreous body.



Fig. S5. Spectral-domain OCT of the retina of patient 2. The spectral-domain OCT of patient 2's retina was performed at 6 months post-injection using Cirrus OCT 5000 (Zeiss). The structure of his fundus showed no obvious exception after the administration of HELP.



Fig. S6. Spectral-domain OCT of the retina of patient 1. The optical coherence tomography revealed mild center-involved intraretinal fluid and subfoveal fluid in the right eye of patient 1 at six months after the treatment. The ellipsoid zone was intact. We continue to follow up on this situation without any intervention.

А



		00 100		1.00001 11.1001	
Channel	N75 [ms]	P100 [ms]	N135 [ms]	N75-P100	P100-N135
1 R1 2,0 deg	70.5	102.2	150.3	8.13µV	13.3µV
2 R1 1,0 deg	76.3	104.5	150.3	3.94µV (!)	11.7µV
3 L1 2,0 deg	62.8	108.0	130.3	6.51µV (!)	4.14µV
4 L1 1,0 deg	70.5	118.0 (!)	125.6	83.5nV (!)	2.01µV

2_Pattern-VEP 30 min&15 min (Monitor)



4 L1 15 min

PVEP: 60'

PVEP: 30'



Fig. S7. Retina ERG of patient 3. The light-stimulated electrical activity of the retina indicates no remarkable change in terms of retinal function in patient 3 (A: pre-injection; B: six months post-injection).

В



PVEP: 30'



Fig. S8. Retina ERG of patient 2. The light-stimulated electrical activity of retina indicates no significant change in terms of retinal function in patient 2 twelve months after the treatment.





Fig. S9. Retinal ERG examination of patient 1. ERG detected no obvious changes of rod or cone responses to light stimulus in patient 1. (A: pre-injection; **B**: twelve months post-injection)

Table S3. Intraocular bacterial and fungal culture results of patient 2. Gram+ cocci were found in the right eye of patient 2 during the vitrectomy 6 months after PK.

Culture	Presence	Species
Bacteria	+	Gram-positive cocci
Fungus	-	-

Patient 1

А



5

Fig. S10. The ECG examination. The pre- and postoperative ECG of patient 1 was unremarkable. (A: pre-injection; B: twelve months post-injection)





Fig. S11. Chest X-ray examination. The Chest X-ray of patient 1 showed no remarkable changes before (**A**) and twelve months (**B**) after the injection.

Code	Pre-Injection		Twelve Months Post-Injection		Normal Range	Unit
White blood cell count	5.24		4.39		4.0~10.0	10^9/L
Red blood cell count	2.71	\downarrow	3.47	\downarrow	4.3~5.8	10^12/L
Hemoglobin	106	\downarrow	122	\downarrow	130~175	g/l
Packed red blood cell volume	30.7	\downarrow	36.9	\downarrow	40~50	%
Red blood cell volume distribution width- coefficient of variation	15.1	Î	15.2	↑	10.0~15.0	%
Red blood cell volume distribution width- standard deviation	62.3	1	59.8	↑	35.0~50.0	fL
Mean corpuscular volume	113.3	1	106.3	↑	80.0~100.0	fL
Mean corpuscular hemoglobin	39.1	1	35.2	↑	27.0~33.0	Pg
Mean corpuscular hemoglobin concentration	345		331		320~360	g/l
Platelet count	175		213		100~400	10^9/L
Platelet distribution width	9.7		11.1		9.0~17.00	
Thrombocytocrit	0.17		0.22		0.16~0.22	%
Mean platelet volume	9.7		10.2		9.0~16.0	fL
Platelet-larger cell ratio	21.6		25.0		14.0~46.0	%
Percentage of neutrophil	61.6		56.2		50.0~70.0	%
Percentage of lymphocyte	32.1		30.8		20.0~40.0	%
Percentage of eosinophil	1.5		3.0		0.5~5.0	%
Percentage of monocyte	4.4		8.9	1	3.0~8.0	%
Percentage of basophil	0.4		1.1	1	0.0~1.0	%
Neutrophil count	3.23		2.47		2.0~7.0	10^9/L
Lymphocyte count	1.68		1.35		0.8~4.0	10^9/L
Monocyte count	0.23		0.39		0.10~0.80	10^9/L
Eosinophil count	0.08		0.13		0.00~0.50	10^9/L
Basophil count	0.02		0.05		0.00~0.10	10^9/L
Code	Pre-Inj	ection	Twelv Post-I	e Months njection	Normal Range	Unit
Alanine aminotransferase	22		31		0~65	u/l
Aspartate aminotransferase	25		30		15~37	u/1
Total protein	67		71		64~82	g/l

Table S4. Blood tests. The blood tests of patient 1 showed slight anemia, hypoproteinemia, and diabetes before the injection. We observed no abnormal changes which were related to the injection in these blood tests at 12-month follow-up.

Albumin	47		43		35~54	g/l
Globulin	20		28		20~40	g/l
Albumin/globulin	2.4		1.5		1.2~2.5	
γ-Glutamyltransferase	55		37		15~85	u/l
Prealbumin	150	\downarrow	200		200~400	mg/l
Alkaline phosphatase	134		137	1	50~136	u/1
Blood urea nitrogen	6.8	1	9.2	1	2.5~6.4	mmol/l
Creatinine	78		90		53~115	umol/l
Uric acid	0.42	↑	0.38	↑	0.202~0.417	mmol/l
Total bilirubin	10		6		0~17	umol/l
Connect bilirubin	5		2		1~5	umol/l
Total bile acid	14.5	1	14.4	↑	0.0~10.0	umol/l
High density lipoprotein	1.73		1.86		0.910~2.060	mmol/l
Low density lipoprotein	1.33		2.21		0.00~3.36	mmol/l
Apoprotein A	1.53		1.28		1.100~1.700	g/l
Apoprotein B	0.56	\downarrow	0.76	\downarrow	0.800~1.550	g/l
Apoprotein E	35		38		27~45	mg/l
Lipoprotein small a	25		42		0~300	mg/l
Small dense low density lipoprotein	0.74		1.20		0.26~1.36	mmol/l
Calcium	2.21		2.21		2.04~2.74	mmol/l
Phosphorus	1.24		1.15		0.80~1.60	mmol/l
Potassium	4.6		4.8		3.5~5.4	mmol/l
Sodium	145		143		135~147	mmol/l
Chloride	109	↑	103		96~108	mmol/l
Carbon dioxide binding capacity	22		24		21~32	mmol/l
Lactate dehydrogenase	172		153		81~234	u/l
Creatine kinase	75		95		39~308	u/l
Complement 3c	0.73	\downarrow	0.71	\downarrow	0.9~1.8	g/l
Complement 4	0.20		0.16		0.1~0.4	g/l
Complement 1q	108.7	\downarrow	117.7	\downarrow	159~233	mg/l
Total complement	68.7	1	62.7	↑	32.5~58.3	u/ml
Haptoglobin	56.50		92.00		32~205	mg/dl
Blood glucose	6.1		6.9	↑	3.9~6.1	mmol/l
Total cholesterol	3.04		4.54		2.80~5.20	mmol/l
Triacylglycerol	0.77		0.70		0.34~2.26	mmol/l

Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
Prothrombin time	13.7	12.7	11.0~14.5	sec
International normalized ratio	1.03	0.98	0.80~1.20	INR
Activated partial thromboplastin time	35.9	32.6	28~45	S
Thrombin time	16.3	17.2	14.0~21.0	S
Fibrinogen	2.70	3.01	2.00~4.00	g/l
D-Dimer	0.67 ↑	0.75 ↑	0.00~0.50	ug/ml
Prothrombin time ratio	95	105	70~150	%
Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
Glycated hemoglobin	6.2 ↑	6.2 ↑	4.0~6.0	%

*Red font denotes an elevated clinical index than the normal range; pink font denotes a decreased clinical index than the normal range. Similarly hereinafter.

Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
Urine glucose	-	-	-	
Ketone body	-	-	-	
Occult blood	-	-	-	
Protein	-	-	-	
Nitrite	-	-	-	
Bilirubin	-	-	-	
Specific gravity	>=1.030 ↑	1.020	1.003~1.030	
Urine PH value	6.0	6.0	5.0~6.5	
Urobilinogen	16	16	3.0~16.0	umol/l
Leukocyte	-	-	-	
White blood cell count	2	2	0~28	/ul
Red blood cell count	1	6	0~17	/ul
Squamous epithelial cells	-	2	0~28	/ul
Non-squamous epithelial cells	-	1	0~6	/ul
Trichomonas	-	-	0~1	/ul
Kidney epithelial cells	-	-	0~6	/ul
Transparent tube	-	-	0~2	/ul
Particle tube	-	-	0~1	/LPF
Cell tube	-	-	0~1	/LPF
Triphosphate crystal	-	-		
Calcium oxalate crystal	-	-		
Leucine crystal	-	-		
Cystine crystals	-	-		

Table S5. Urine tests. The pre-injection and twelve months post-injection routine urinalysis of patient 1 was unremarkable.

Code	Pre-Injection	Twelve Months Post- Injection
Hepatitis B virus surface antigen	Negative	Negative
Hepatitis B virus surface antibody	Negative	Negative
Hepatitis B virus e antigen	Negative	Negative
Hepatitis B virus e antibody	Negative	Negative
Hepatitis B virus core antibody	Negative	Negative
Hepatitis B virus antibody-immunoglobin M	Negative	Negative
Hepatitis B virus pre-S1 antigen	Negative	Negative
Hepatitis C virus antibody	Negative	Negative
Treponema pallidum particle agglutination test	Negative	Negative
Rapid plasma regain test	Negative	Negative
Human immunodeficiency virus antibody	Negative	Negative

Table S6. Infectious diseases tests. The four transfusion-associated contagion tests (hepatitis B, hepatitis C, syphilis, AIDS) of patient 1 were unremarkable.

Patient 2



Fig. S12. The ECG. The ECG of patient 2 showed counterclockwise transposition, indicating a possibly hypertrophic in the left ventricle. Slightly hypertrophy of the ventricle is not reckoned as a contraindication for corneal transplant surgery.



Fig. S13. Chest X-ray film. The chest X-ray result of patient 2 was unremarkable.

Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
White blood cell count	7.17	10.16 ↑	4.0~10.0	10^9/L
Red blood cell count	4.73	4.69	4.3~5.8	10^12/L
Hemoglobin	148	144	130~175	g/l
Packed red blood cell volume	44.0	43.1	40~50	%
Red blood cell volume distribution width- coefficient of variation	12.1	12.9	10.0~15.0	%
Red blood cell volume distribution width- standard deviation	41.6	43.1	35.0~50.0	fL
Mean corpuscular volume	93.0	91.9	80.0~100.0	fL
Mean corpuscular hemoglobin	31.3	30.7	27.0~33.0	Pg
Mean corpuscular hemoglobin concentration	336	334	320~360	g/l
Platelet count	229	236	100~400	10^9/L
Platelet distribution width	9.3	9.8	9.0~17.00	
Thrombocytocrit	0.21	0.22	0.16~0.22	%
Mean platelet volume	9.1	9.2	9.0~16.0	fL
Platelet-larger cell ratio	17.7	18.4	14.0~46.0	%
Percentage of neutrophil	64.3	77.8 ↑	50.0~70.0	%
Percentage of lymphocyte	28.7	18.3 ↓	20.0~40.0	%
Percentage of eosinophil	1.0	0.3 ↓	0.5~5.0	%
Percentage of monocyte	5.6	3.1	3.0~8.0	%
Percentage of basophil	0.4	0.5	0.0~1.0	%
Neutrophil count	4.61	7.9 ↑	2.0~7.0	10^9/L
Lymphocyte count	2.06	1.86	0.8~4.0	10^9/L
Monocyte count	0.40	0.32	0.10~0.80	10^9/L
Eosinophil count	0.07	0.03	0.00~0.50	10^9/L
Basophil count	0.03	0.05	0.00~0.10	10^9/L
Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
Alanine aminotransferase	17	19	0~65	u/l
Aspartate aminotransferase	17	15	15~37	u/l
Total protein	70	68	64~82	g/l

Table S7. Blood tests. The blood tests of patient 2 indicated mild hyperlipidemia, which had no obvious influence on the implementation of the surgery. We observed no notable changes related to the injection in these blood tests at 12-month follow-up.

Albumin	46		42		35~54	g/l
Globulin	24		26		20~40	g/l
Albumin/globulin	1.9		1.6		1.2~2.5	
γ-Glutamyltransferase	33		37		15~85	u/l
Prealbumin	320		350		200~400	mg/l
Alkaline phosphatase	71		80		50~136	u/l
Blood urea nitrogen	5.5		7.5	↑	2.5~6.4	mmol/l
Creatinine	69		62		53~115	umol/l
Uric acid	0.25		0.32		0.202~0.417	mmol/l
Total bilirubin	16		10		0~17	umol/l
Connect bilirubin	5		2		1~5	umol/l
Total bile acid	2.5		11.2	↑	0.0~10.0	umol/l
High density lipoprotein	1.24		1.61		0.910~2.060	mmol/l
Low density lipoprotein	4.36	1	4.72	↑	0.00~3.36	mmol/l
Apoprotein A	1.46		1.24		1.100~1.700	g/l
Apoprotein B	1.51		1.55		0.800~1.550	g/l
Apoprotein E	52	1	46	↑	27~45	mg/l
Lipoprotein small a	41		47		0~75	nmol/l
Small dense low density lipoprotein	3.11	1	2.70	↑	0.26~1.36	mmol/l
Calcium	2.34		2.25		2.04~2.74	mmol/l
Phosphorus	1.18		0.99		0.80~1.60	mmol/l
Potassium	4.2		4.0		3.5~5.4	mmol/l
Sodium	140		142		135~147	mmol/l
Chloride	104		101		96~108	mmol/l
Carbon dioxide binding capacity	23		21		21~32	mmol/l
Lactate dehydrogenase	168		182		81~234	u/l
Creatine kinase	122		128		39~308	u/l
Complement 3c	1.03		1.04		0.9~1.8	g/l
Complement 4	0.20		0.32		0.1~0.4	g/l
Complement 1q	154.5	\downarrow	169.4		159~233	mg/l
Total complement	67.9	1	63.5	↑	32.5~58.3	u/ml
Haptoglobin	93.30		110.50	0	32~205	mg/dl
Blood glucose	5.6		6.1		3.9~6.1	mmol/l
Total cholesterol	6.12	1	7.04	↑	2.80~5.20	mmol/l
Triacylglycerol	2.33	↑	1.81		0.34~2.26	mmol/l

Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
Prothrombin time	13.3	12.4	11.0~14.5	sec
International normalized ratio	0.99	0.95	0.80~1.20	INR
Activated partial thromboplastin time	35.3	33.0	28~45	S
Thrombin time	18.7	19.7	14.0~21.0	S
Fibrinogen	2.98	2.74	2.00~4.00	g/l
D-Dimer	0.24	0.23	0.00~0.50	ug/ml
Prothrombin time ratio	102	110	70~150	%
Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
Glycated hemoglobin	5.9	5.9	4.0~6.0	%

Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
Urine glucose	-	-	-	
Ketone body	-	-	-	
Occult blood	-	-	-	
Protein	-	-	-	
Nitrite	-	-	-	
Bilirubin	-	-	-	
Specific gravity	>=1.030 ↑	1.025	1.003~1.030	
Urine PH value	5.5	6.0	5.0~6.5	
Urobilinogen	3.2	16	3.0~16.0	umol/l
Leukocyte	-	-	-	
White blood cell count	6	6	0~28	/ul
Red blood cell count	2	2	0~17	/ul
Squamous epithelial cells	2	1	0~28	/ul
Non-squamous epithelial cells	-	1	0~6	/ul
Trichomonas	-	-	0~1	/ul
Kidney epithelial cells	-	-	0~6	/ul
Transparent tube	-	-	0~2	/ul
Particle tube	-	-	0~1	/LPF
Cell tube	-	-	0~1	/LPF
Triphosphate crystal	-	-		
Calcium oxalate crystal	-	-		
Leucine crystal	-	-		
Cystine crystals	-	-		

Table S8. Routine urine test. The routine urinalysis of patient 2 was unremarkable.

Table S9. Transfusion-associated contagion tests. The contagion tests of patient 2 showed specific antibodies to the hepatitis B virus. The other three transfusion-associated contagion tests (hepatitis C, syphilis, AIDS) were negative.

Code	Pre-Injection	Twelve Months Post- Injection
Hepatitis B virus surface antigen	Negative	Negative
Hepatitis B virus surface antibody	Weak Positive	Weak Positive
Hepatitis B virus e antigen	Negative	Negative
Hepatitis B virus e antibody	Negative	Negative
Hepatitis B virus core antibody	Positive	Positive
Hepatitis B virus antibody-immunoglobin M	Negative	Negative
Hepatitis B virus pre-S1 antigen	Negative	Negative
Hepatitis C virus antibody	Negative	Negative
Treponema pallidum particle agglutination test	Negative	Negative
Rapid plasma regain test	Negative	Negative
Human immunodeficiency virus antibody	Negative	Negative

Patient 3



Fig. S14. The ECG examination. The pre-operative ECG of patient 3 was unremarkable.

5



Fig. S15. Chest X-ray film. The chest X-ray result of patient 3 was unremarkable.

Code	Pre-Injection	Six Months Post- Injection	Normal Range	Unit
White blood cell count	5.45	4.83	4.0~10.0	10^9/L
Red blood cell count	5.28	4.89	4.3~5.8	10^12/L
Hemoglobin	159	152	130~175	g/l
Packed red blood cell volume	46.1	42.8	40~50	%
Red blood cell volume distribution width- coefficient of variation	11.9	12.4	10.0~15.0	%
Red blood cell volume distribution width- standard deviation	37.6	39.0	35.0~50.0	fL
Mean corpuscular volume	87.3	87.5	80.0~100.0	fL
Mean corpuscular hemoglobin	30.1	31.1	27.0~33.0	Pg
Mean corpuscular hemoglobin concentration	345	355	320~360	g/l
Platelet count	151	105	100~400	10^9/L
Platelet distribution width	10.8	12.2	9.0~17.00	
Thrombocytocrit	0.14 ↓	0.11 ↓	0.16~0.22	%
Mean platelet volume	9.5	10.7	9.0~16.0	fL
Platelet-larger cell ratio	21.5	30.8	14.0~46.0	%
Percentage of neutrophil	62.3	57.7	50.0~70.0	%
Percentage of lymphocyte	29.7	32.4	20.0~40.0	%
Percentage of eosinophil	1.7	2.3	0.5~5.0	%
Percentage of monocyte	5.9	7.3	3.0~8.0	%
Percentage of basophil	0.4	0.3	0.0~1.0	%
Neutrophil count	3.40	2.21	2.0~7.0	10^9/L
Lymphocyte count	1.62	1.24	0.8~4.0	10^9/L
Monocyte count	0.32	0.28	0.10~0.80	10^9/L
Eosinophil count	0.09	0.09	0.00~0.50	10^9/L
Basophil count	0.02	0.01	0.00~0.10	10^9/L
Code	Pre-Injection	Six Months Post- Injection	Normal Range	Unit
Alanine aminotransferase	29	53	0~65	u/l
Aspartate aminotransferase	18	26	15~37	u/l
Total protein	76	65	64~82	g/l
Albumin	49	40	35~54	g/1

Table S10. Blood tests. The blood tests of patient 3 indicated mild hyperlipidemia, which had no obvious influence on the implementation of the surgery.

Globulin	27		24		20~40	g/l
Albumin/globulin	1.8		1.66		1.2~2.5	
γ-Glutamyltransferase	37		49		15~85	u/l
Prealbumin	350		310		200~400	mg/l
Alkaline phosphatase	95		103		50~136	u/l
Blood urea nitrogen	6.6	1	5.6		2.5~6.4	mmol/l
Creatinine	78		77		53~115	umol/l
Uric acid	0.32		0.37		0.202~0.417	mmol/l
Total bilirubin	16		16		0~17	umol/l
Connect bilirubin	7	↑	3		1~5	umol/l
Total bile acid	6		2		0.0~10.0	umol/l
High density lipoprotein	1.16		0.84	\downarrow	0.910~2.060	mmol/l
Low density lipoprotein	2.79		2.24		0.00~3.36	mmol/l
Apoprotein A	1.29		1.00	\downarrow	1.100~1.700	g/l
Apoprotein B	1.000		0.800		0.800~1.550	g/l
Apoprotein E	39		35		27~45	mg/l
Lipoprotein small a	38		42		0~75	nmol/l
Small dense low density lipoprotein	1.90	1	1.87	1	0.26~1.36	mmol/l
Calcium	2.32		2.32		2.04~2.74	mmol/l
Phosphorus	0.97		1.23		0.80~1.60	mmol/l
Potassium	4.3		4.4		3.5~5.4	mmol/l
Sodium	140		139		135~147	mmol/l
Chloride	102		105		96~108	mmol/l
Carbon dioxide binding capacity	26		23		21~32	mmol/l
Lactate dehydrogenase	149		175		81~234	u/l
Creatine kinase	75		98		39~308	u/l
Complement 3c	1.07		1.12		0.9~1.8	g/l
Complement 4	0.31		0.29		0.1~0.4	g/l
Complement 1q	195.5		210.4		159~233	mg/l
Total complement	82.5	1	84.7	1	32.5~58.3	u/ml
Haptoglobin	86.50		98.20		32~205	mg/dl
Blood glucose	5.7		4.7		3.9~6.1	mmol/l
Total cholesterol	4.36		3.68		2.80~5.20	mmol/l
Triacylglycerol	1.23		2.24		0.34~2.26	mmol/l

Code	Pre-Injection	Six Months Post- Injection	Normal Range	Unit
Prothrombin time	13.3	11.1	11.0~14.5	sec
International normalized ratio	1.00	0.94	0.80~1.20	INR
Activated partial thromboplastin time	37.7	32.8	28~45	S
Thrombin time	18.0	16.8	14.0~21.0	S
Fibrinogen	3.43	2.72	2.00~4.00	g/l
D-Dimer	0.28	0.31	0.00~0.50	ug/ml
Prothrombin time ratio	99	97	70~150	%
Code	Pre-Injection	Six Months Post- Injection	Normal Range	Unit
Glycated hemoglobin	5.3	4.89	4.0~6.0	%

Code	Pre-Injection Results	Normal Unit Range
Urine glucose	-	-
Ketone body	-	-
Occult blood	-	-
Protein	-	-
Nitrite	-	-
Bilirubin	-	-
Specific gravity	>=1.030 ↑	1.003~1.030
Urine PH value	7.0 ↑	5.0~6.5
Urobilinogen	3.2	3.0~16.0 umol/l
Leukocyte	-	-
White blood cell count	1	0~28 /ul
Red blood cell count	1	0~17 /ul
Squamous epithelial cells	-	0~28 /ul
Non-squamous epithelial cells	-	0~6 /ul
Trichomonas	-	0~1 /ul
Kidney epithelial cells	-	0~6 /ul
Transparent tube	-	0~2 /ul
Particle tube	-	0~1 /LPF
Cell tube	-	0~1 /LPF
Triphosphate crystal	-	
Calcium oxalate crystal	-	
Leucine crystal	-	
Cystine crystals	-	

 Table S11. Routine urine test. The routine urinalysis of patient 3 was unremarkable.

Code	Pre-Injection Results
Hepatitis B virus surface antigen	Negative
Hepatitis B virus surface antibody	Positive
Hepatitis B virus e antigen	Negative
Hepatitis B virus e antibody	Positive
Hepatitis B virus core antibody	Positive
Hepatitis B virus antibody-immunoglobin M	Negative
Hepatitis B virus pre-S1 antigen	Negative
Hepatitis C virus antibody	Negative
Treponema pallidum particle agglutination test	Negative
Rapid plasma regain test	Negative
Human immunodeficiency virus antibody	Negative

Table S12. Transfusion-associated contagion tests. The contagion tests of patient 3 showed specific antibodies to the hepatitis B virus. The other three transfusion-associated contagion tests (hepatitis C, syphilis, AIDS) were negative.



Fig. S16. ELISA results detect antibodies against SpCas9. Tetanus toxoid and human albumin in the sera from different donors served as a positive and negative control, respectively. The Cas9-specific antibodies were determined at different time points. The change in Cas9 antibody levels before and after HELP administration was insignificant. All samples above the dotted line were considered antibody-positive. The dotted line represents the mean absorbance of the negative control, human albumin, plus three s.d. from the mean. Data and error bars represent mean \pm s.e.m.; n.s., non-significant; unpaired two-tailed Student's t-tests.



Fig. S17. In vitro antiviral activity of the clinical grade HELP. 4×104 293T cells were seeded in a 48-well plate and transduced with 400 ng of HELP or scramble control on the following day. The medium was refreshed 12 h post-infection (h.p.i.). 24 h after transduction, cells were infected with HSV-1-GFP at an MOI of 1. The cells and supernatants were harvested at 24 and 48 h.p.i. for flow cytometry (A) and plaque assay (B), respectively. 293T cells were transduced with HELP for 24 h and then infected with HSV-1-GFP. n=3 biologically independent samples. Data and error bars represent mean \pm s.e.m.; n.s., non-significant; ***P<0.001; unpaired two-tailed Student's t-tests.



Fig. S18. Gating strategies used for cell sorting analysis. Gate strategy to sort GFP positive cells from HSV1-GFP infected 293T cells on supplementary figure S17a.



Fig. S19. Validity of patient samples. GAPDH gene in the tear swab of patients was tested by PCR to verify the validity of patient samples. Eye swab samples of 1 day pre-injection, 1 month, 6 months, 12 months post-injection of patient 1 & 2, and samples of 1 day pre-injection, 1 month, 3 months, 6 months post-injection of patient 3 were used as templates for PCR followed by nucleic acid gel electrophoresis. The results showed that GAPDH was positive in all samples, indicating that the swabs were valid.



Fig. S20. Gene editing efficiency of the clinical grade HELP. TIDE analysis of indels in the HSV-1 genome. 2×104 293T cells were incubated with 200 ng P24 HELP, then infected with HSV-1 with MOI=1. Virus DNA was collected at 2 days post-infection for Sanger sequencing. n=3 biologically independent samples.

Target	gRNA Sequence (5'-3')	Primer	Sequence (5'-3')
sites		names	
UL8	GGGGCAGCCATACCGCGTAA	Y1-F	gagccgtagaaatcccgcag
		Y2-R	aaacctcaccaaacagacaa
UL29	GCGAGCGTACACGTATCCC	Y3-F	gggtgtagtccgaaaagccaa
		Y4-R	cacgcccccaggtaaagtgta

 Table S13. The primers for UL8 and UL29 amplification.

Source	OBiO Technology (Shanghai) Corp., Ltd.		Specification	0.25 ml/vial
Test Cat	egory	Test	Result	
Quantifi	cation	p24 protein content	1.19E+04 ng p2	4/ml
		Bacteria	Negative	
Safety		Mycoplasma	Negative	
Conclus	ion	Qualified		

 Table 14. The quality report of HELP.

Continue f	Detienel.	Comment Viewiew
Section of	Kationale	Current Version
Current protocol		
Outcomes	Adjust the contents	Primary outcome: HSV-1 testing outcome of
Measures	and priorities of	the intervention eye; adverse effects.
	outcomes	Secondary outcome: patient graft survival;
		best-corrected visual acuity.
2.1	Adjust the inclusion	Patients with refractory keratitis caused by
	criteria	herpes virus type I who has acute corneal
		perforation or had at least one time failed
		corneal transplant due to the virus relapse.

Table S15. The list of protocol changes.